Abstract
Metastatic castration-resistant prostate cancer (mCRPC) is universally incurable and represents an area of substantial unmet medical need. Novel targets and therapeutic strategies have emerged based on an improved understanding of the crosstalk between prostate cancer cells and the bone microenvironment. A wide variety of signaling systems including the RANKL/RANK/OPG, IGF-I, FGF and Wnt:DKK-1 pathways can be targeted to suppress tumor growth and treatment resistance. Antisurvival factor therapy can increase the efficacy of standard antineoplastic regimens by targeting biologic molecules acting as “survival factors” within the bone microenvironment. Novel agents can also be used to mobilize the host immune system to attack prostate cancer cells. Clinical testing of these therapeutic approaches has produced encouraging objective clinical responses in subsets of patients with mCRPC. The present review summarizes data regarding the emerging strategies used to target the bone microenvironment in mCRPC.
Keywords: Bone metastasis, castration-resistant prostate cancer, tumor microenvironment.
Current Drug Targets
Title:Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Volume: 17 Issue: 3
Author(s): Pavlos Msaouel, Jose Nahun Galeas, Alejandro Recio Boiles, Ramiro Rancier Ruiz and Michael Koutsilieris
Affiliation:
Keywords: Bone metastasis, castration-resistant prostate cancer, tumor microenvironment.
Abstract: Metastatic castration-resistant prostate cancer (mCRPC) is universally incurable and represents an area of substantial unmet medical need. Novel targets and therapeutic strategies have emerged based on an improved understanding of the crosstalk between prostate cancer cells and the bone microenvironment. A wide variety of signaling systems including the RANKL/RANK/OPG, IGF-I, FGF and Wnt:DKK-1 pathways can be targeted to suppress tumor growth and treatment resistance. Antisurvival factor therapy can increase the efficacy of standard antineoplastic regimens by targeting biologic molecules acting as “survival factors” within the bone microenvironment. Novel agents can also be used to mobilize the host immune system to attack prostate cancer cells. Clinical testing of these therapeutic approaches has produced encouraging objective clinical responses in subsets of patients with mCRPC. The present review summarizes data regarding the emerging strategies used to target the bone microenvironment in mCRPC.
Export Options
About this article
Cite this article as:
Msaouel Pavlos, Galeas Nahun Jose, Boiles Recio Alejandro, Ruiz Rancier Ramiro and Koutsilieris Michael, Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450116666150420143932
DOI https://dx.doi.org/10.2174/1389450116666150420143932 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Fireflies in the Coalmine: Luciferase Technologies in Next-Generation Toxicity Testing
Combinatorial Chemistry & High Throughput Screening Molecular Docking Analysis of Flavonoid Compounds with Matrix Metalloproteinase- 8 for the Identification of Potential Effective Inhibitors
Letters in Drug Design & Discovery Doxorubicin-Induced In Vivo Nephrotoxicity Involves Oxidative Stress- Mediated Multiple Pro- and Anti-Apoptotic Signaling Pathways
Current Neurovascular Research Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand
Current Radiopharmaceuticals Anti-Cancer Activities of Tea Epigallocatechin-3-Gallate in Breast Cancer Patients under Radiotherapy
Current Molecular Medicine Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways
Current Drug Targets Therapeutic Potential for Thyroid Hormone Receptor-β Selective Agonists for Treating Obesity, Hyperlipidemia and Diabetes
Current Vascular Pharmacology Tumor-Induced Alterations in Lipid Metabolism
Current Medicinal Chemistry Synthesis, Biological Evaluation, Molecular Docking Study and Acute Oral Toxicity Study of Coupled Imidazole-Pyrimidine Derivatives
Letters in Drug Design & Discovery Radionuclide Antibody-Conjugates, a Targeted Therapy Towards Cancer
Current Radiopharmaceuticals Plant Spliceosomal Introns: Not Only Cut and Paste
Current Genomics Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Current Diabetes Reviews Solid-State Structure of Abeta (Aβ) in Alzheimer's Disease
Protein & Peptide Letters Radioprotective Effect of Gliclazide as an Anti-Hyperglycemic Agent Against Genotoxicity Induced by Ionizing Radiation on Human Lymphocytes
Cardiovascular & Hematological Agents in Medicinal Chemistry Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science Immunotoxins and Neuropeptide-Toxin Conjugates Experimental Applications
Mini-Reviews in Medicinal Chemistry Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Anti-Cancer Agents in Medicinal Chemistry